GBM Clinical Trials

57 recruitingLast updated: June 17, 2026

There are 57 actively recruiting gbm clinical trials across 20 countries. Studies span Phase 2, Phase 1, Not Applicable, Early Phase 1, Phase 3. Top locations include New York, New York, United States, Phoenix, Arizona, United States, Philadelphia, Pennsylvania, United States. Updated daily from ClinicalTrials.gov.


GBM Trials at a Glance

57 actively recruiting trials for gbm are listed on ClinicalTrialsFinder across 6 cities in 20 countries. The largest study group is Phase 2 with 22 trials, with the heaviest enrollment activity in New York, Phoenix, and Philadelphia. Lead sponsors running gbm studies include Northwell Health, Institute of Cancer Research, United Kingdom, and Nader Sanai.

Treatments under study

About GBM Clinical Trials

Looking for clinical trials for GBM? There are currently 18 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new GBM trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about GBM clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 57 trials

Recruiting
Not Applicable

The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma

Glioblastoma (GBM)IDH Wildtype Glioblastoma
Ottawa Hospital Research Institute50 enrolled2 locationsNCT06850766
Recruiting
Phase 1Phase 2

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Brain CancerGBMGlioma+12 more
National Institute of Neurological Disorders and Stroke (NINDS)40 enrolled1 locationNCT07416188
Recruiting
Early Phase 1

Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-WildtypeGlioblastoma (GBM)Recurrent Glioblastoma+1 more
Beijing Tiantan Hospital5 enrolled2 locationsNCT07648823
Recruiting
Phase 2

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Central Nervous System DiseasesBrain CancerGlioblastoma Multiforme (GBM)+4 more
Black Diamond Therapeutics, Inc.162 enrolled13 locationsNCT07326566
Recruiting
Not Applicable

Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM)

Glioblastoma (GBM)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins35 enrolled1 locationNCT07375992
Recruiting
Phase 2

Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

GlioblastomaGBM
Alpheus Medical, Inc.103 enrolled10 locationsNCT07225621
Recruiting
Phase 1Phase 2

Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma

Glioblastoma (GBM)Recurrent GlioblastomaNewly Diagnosed Glioblastoma+1 more
Trogenix ltd68 enrolled2 locationsNCT07346144
Recruiting
Phase 3

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

GlioblastomaGBMRecurrent Glioblastoma
CarThera560 enrolled48 locationsNCT05902169
Recruiting
Phase 1Phase 2

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

ParagangliomaPheochromocytomaSolid Tumor Cancer+19 more
Fundación de investigación HM25 enrolled1 locationNCT06607692
Recruiting
Not Applicable

Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening: Advanced Brain Tumor TheRApy Clinical Trial In Patients Scheduled for shOrt Course radiatioN

Glioblastoma (GBM)
Medical University of Vienna30 enrolled1 locationNCT07627334
Recruiting
Phase 1Phase 2

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

CancerBrain TumorBrain Cancer+6 more
Northwell Health67 enrolled1 locationNCT03213002
Recruiting
Phase 1Phase 2

Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

Brain TumorBrain CancerGlioblastoma+4 more
Northwell Health33 enrolled1 locationNCT02861898
Recruiting
Not Applicable

Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma

Brain CancerGlioblastomaGBM+4 more
Northwell Health32 enrolled1 locationNCT05954858
Recruiting
Not Applicable

LITT for Ultra-early GBM Recurrence

Glioblastoma (GBM)Glioblastoma - Category
Insel Gruppe AG, University Hospital Bern12 enrolled1 locationNCT07616986
Recruiting
Not Applicable

Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)

Brain CancerGlioblastomaGBM+5 more
Northwell Health10 enrolled1 locationNCT05979064
Recruiting
Phase 3

Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM

Brain CancerGlioblastomaGBM+4 more
Northwell Health432 enrolled1 locationNCT05271240
Recruiting

Mental Health and Suicidality in Glioblastoma Patients in Germany

Glioblastoma (GBM)
University Hospital, Essen176 enrolled6 locationsNCT07409584
Recruiting
Early Phase 1

BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors

Glioblastoma (GBM)
Nader Sanai78 enrolled1 locationNCT07485049
Recruiting
Phase 1

Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma

Glioblastoma (GBM)
University of Virginia12 enrolled1 locationNCT07343986
Recruiting
Phase 2

G-CSF After Chemo-radiation in Patients With Glioblastoma

Glioblastoma (GBM)MGMT-Methylated GlioblastomaNewly Diagnosed Glioblastoma Multiforme
Massachusetts General Hospital60 enrolled1 locationNCT06649851